Notably, the treatment group had similar ratios of CD4+/CD45+ cells before tumor rechallenge; however, the treatment group had a significantly higher ratio of CD4+/CD45+ cells (46.9% ± 1.3% vs. 33.3% ± 0.6%) after tumor rechallenge, compared with the control group. This evidence concerns the gene PTPRC and neoplasm.